Expression of CD137 on hodgkin and reed-sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression

Cancer Research

Volumn 73, Issue 2, 2013, Pages 652-661

  Ho, Weng Tong ^a,b   Pang, Wan Lu ^a,b   Chong, Siew Meng ^a   Castella, Antonio ^d   Al Salam, Suhail ^d   Tan, Teng Ee ^a,b   Moh, Mei Chung ^a,b   Koh, Liang Kai ^a,b   Gan, Shu Uin ^a   Cheng, Cheong Kin ^a,b   Schwarz, Herbert ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; GAMMA INTERFERON; TNFSF9 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMBRANE BIOLOGY; PRIORITY JOURNAL; REED STERNBERG CELL; T LYMPHOCYTE ACTIVATION; TROGOCYTOSIS;

4-1BB LIGAND; ANTIGENS, CD137; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; REED-STERNBERG CELLS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84872532787     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3849     Document Type: Article

References (43)

1. Kuppers R. Molecular biology of Hodgkin lymphoma. HematolAmSoc Hematol Educ Program 2009: 491-6.
2. Aldinucci D, Gloghini A, Pinto A, De FR, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221: 248-63.
3. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220: 82-101.
4. Thomas-Kaskel AK, Waller CF, Schultze-Seemann W, Veelken H. Immunotherapy with dendritic cells for prostate cancer. Int J Cancer 2007;121: 467-73.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3: 991-8.
6. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104: 13134-9.
7. Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007;110: 1326-9.
8. Chemnitz JM, Driesen J, Classen S, Riley JL, Debey S, Beyer M, et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 2006;66: 1114-22.
9. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111: 3220-4.
10. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003;81: 281-7.
11. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103: 1755-62.
12. Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci 2009;14: 4173-88.
13. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229: 192-215.
14. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9: 271-85.
15. Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol 2010;344: 245-67.
16. DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade WF, Kwon BS, et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995; 181: 985-92.
17. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002;168: 4897-906.
18. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 353-66.
19. Schwarz H. Biological activities of reverse signal transduction through CD137 ligand. J Leukoc Biol 2005;77: 281-6.
20. Shao H, Fu Y, Liao T, Peng Y, Chen L, Kaplan HJ, et al. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci 2005;46: 596-603.
21. Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998;160: 2488-94.
22. Langstein J, Michel J, Schwarz H. CD137 induces proliferation and endomitosis in monocytes. Blood 1999;94: 3161-8.
23. Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, et al. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 2007;21: 456-63.
24. Lippert U, Zachmann K, Ferrari DM, Schwarz H, Brunner E, Latif AH, et al. CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 2008;38: 1024-32.
25. Ju S, Ju S, Ge Y, Qiu H, Lu B, Qiu Y, et al. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol 2009;21: 1135-44.
26. Kwajah MMS, Schwarz H. CD137ligandsignaling induces humanmonocyte to dendritic cell differentiation. Eur J Immunol 2010;40: 1938-49.
27. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002;72: 35-42.
28. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand J Immunol 2003;57: 305-10.
29. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3: 682-5.
30. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162: 5003-10.
31. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 2007;7: 238-43.
32. Caumartin J, Lemaoult J, Carosella ED. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity. Transpl Immunol 2006;17: 20-2.
33. Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010;70: 3945-54.
34. Palma C, Binaschi M, Bigioni M, Maggi CA, Goso C. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer 2004;108: 390-8.
35. Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol 2012;181: 795-803.
36. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995;155: 3360-7.
37. Furtner M, Straub RH, Kruger S, Schwarz H. Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia 2005;19: 883-5.
38. Foell J, McCausland M, Burch J, Corriazzi N, Yan XJ, Suwyn C, et al. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann NY Acad Sci 2003;987: 230-5.
39. Foell JL, ez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004;113: 89-98.
40. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, et al. 4-1BBmediated immunotherapy of rheumatoid arthritis. Nat Med 2004;10: 1088-94.
41. Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Wacker A, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010;115: 3058-69.
42. Daubeuf S, Puaux AL, Joly E, Hudrisier D. A simple trogocytosisbased method to detect, quantify, characterize and purify antigenspecific live lymphocytes by flow cytometry, via their capture of membrane fragments from antigen-presenting cells. Nat Protoc 2006;1: 2536-42.
43. Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, et al. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones. J Immunol 2012;188: 632-40.